【摘要】 目的 观察利伐沙班与华法林在预防60岁以上2型糖尿病（T2DM）伴非瓣膜病性心房颤动（NVAF）患者血栓栓塞的疗效和安全性。方法 以现有的112名患2型糖尿病伴非瓣膜病性心房颤动病人作为实验对象，然后遵循随机原则，平均将其分成2组，分别是:利伐沙班组、华法林组，两组各有56例患者。给药后每月随访1次，为期1年，观察记录用药期间新发的血栓栓塞和出血事件。结果 共有110人完成本次研究，华法林组2例中途退出，无死亡病例。利伐沙班组出血率为5.4％，有效率达到100%；而华法林组的两种比率分别为18.5%，98.1％，出血率明细高于利伐沙班组，有效率明显低于利伐沙班组。结论 两种药物相比，利伐沙班在预防60岁以上患2型糖尿病（T2DM）伴非瓣膜病性心房颤动（NVAF）疗效相当，安全性能更好，值得应用推广。
【关键词】2型糖尿病；非瓣膜病性房颤；利伐沙班；华法林
Clinical observation of rivaroxaban combined with warfarin in the treatment of type 2 diabetes mellitus with nonvalvular atrial fibrillation over 60 years old
ZHANG Zhong-yuan，YANG Xiao-jun. Department of Geriatrics，Nanjing Tongren Hospital affiliated medical college of southeast university，Naijing 232001，China
【Abstract】Objective In order to watch the curative effect and security of Rivaroxaban and warfarin in stopping thromboembolism in patients more than 60 years old with type 2 diabetes mellitus (T2DM) complicated with non-valvular atrial fibrillation (NVAF). Methods 112 T2DM patients suffer from NVAF were divided into randomly two groups: warfarin group (56 cases) and rivaroxaban group (56 cases) . The patients were followed up once a month for one year to observe and record the new thromboembolism and bleeding events.
Results A total of 110 people completed the study. 2 patients in the warfarin group dropped out without death. The effective rate and the incidence of bleeding events in rivaroxaban group were (100%, 5.4%)., and those in warfarin group were (98.1%, 18.5%). Conclusions Compared with warfarin, rivaroxaban has the same efficacy and higher safety in preventing thromboembolism in patients with type 2 diabetes mellitus with non-valvular atrial fibrillation.
【Key words】type 2 diabetes mellitus ;Non-valvular atrial fibrillation ; Rivaroxaban ; Warfarin
评论0